Noxopharm Limited

NOX

AU000000NOX9

Pharmaceuticals

Delayed Australian S.E. Other stock markets 01:56:02 2024-05-17 am EDT			5-day change	1st Jan Change
0.072 ^AUD	-7.69%		+14.29%	+1.41%

Apr. 04	Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug	MT
Feb. 27	Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive	MT

Noxopharm Limited Announces Executive Changes

February 20, 2019 at 04:47 pm EST

Noxopharm Limited announced that Dr. Graham Kelly moves to Group CEO, with overall responsibility for Noxopharm and its subsidiary, Nyrada Inc., ahead of anticipated growing interest in both companies in both the Australian and U.S. investment markets and the global pharmaceutical industry. Dr. Greg van Wyk, previously the chief medical officer of Noxopharm, assumes the CEO role in addition to CMO duties. Dr. Gisela Mautner MD PhD MPH MBA FACPE has been appointed Global Medical Director focusing on the global Veyonda clinical trial program.

Latest news about Noxopharm Limited

Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug	Apr. 03	MT
Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive	Feb. 27	MT
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Noxopharm Extends Strategic Partnership with Hudson Institute of Medical Research	Feb. 12	MT
Noxopharm Receives AU$6.1 Million R&D tax Rebate; Shares Up 8%	Nov. 15	MT
Concerns of Further US Monetary Tightening Push Australian Shares to Nearly 11-Month Low	23-10-04	MT
US FDA Grants Orphan Drug Status to Noxopharm's Pancreatic Cancer Drug; Shares Surge 73%	23-10-04	MT
Noxopharm Validates Efficacy of Cancer Treatment in Animal Study; Shares Rally 13%	23-09-28	MT
Noxopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
NobleOak Life Secures Approval from Financial Services Regulator for Reporting Standards	23-07-03	MT
Noxopharm Limited Announces Change of Registered Office and Principal Place of Business	23-06-18	CI
Study Finds Noxopharm's New SOF-XX Drug Reduces Inflammation	23-05-19	MT
Noxopharm's NOXO Options to Expire June 18; Shares Down 17%	23-05-08	MT
Noxopharm to Discontinue Veyonda Trials; to Focus on Chroma, Sofra Platforms; Shares Plummet 41%	23-04-06	MT
Noxopharm to Develop Vaccine Enhancer; Shares Rise 3%	23-03-27	MT
Noxopharm Limited Announces Novel mRNA Vaccine Enhancer	23-03-27	CI
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Noxopharm Limited to Present Sofra Study at Lupus 2023 Conference	23-02-21	CI
NobleOak Life to Release Shares from Voluntary Escrow	23-02-08	MT
Noxopharm Advances to the Efficacy Portion of its Phase 2 Prostate Cancer Trial	23-01-17	MT
Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial	23-01-16	CI
Noxopharm's Strategic Partner Secures Grant Funding from the Australian Government	22-12-15	MT
Noxopharm Receives Innovation Connections Grant; Shares Fall 5%	22-12-05	MT
Noxopharm Limited Announces Award of Federal Innovation Connections Grant	22-12-05	CI
Noxopharm Advances Phase 1 Cancer Drug Trial Following Safety Clearance	22-12-02	MT

Chart Noxopharm Limited

Duration

Period

More charts

Company Profile

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
NOXOPHARM LIMITED	+1.41%	14.06M
CSL LIMITED	-2.59%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals